Preventative Maintenance, Emergency Service, support, and coverage for Illumina NovaSeq 6000 Sequencing System.

The Department of Health and Human Services (DHHS), National Institutes of Health, National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology (LP) plans to procure, on a sole source basis, Preventive Maintenance, Emergency Service, Support, and Coverage for a Government-Owned Illumina NovaSeq 6000 Sequencing System from: Illumina, Inc. 5200 Illumina Way San Diego, CA 92122-4616 The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 811219 for which the small business size standard is $22.0 million. The Government-owned NovaSeq 6000 sequencing system must be calibrated accurately and maintained according to the manufacturer’s specifications by authorized Original Equipment Manufacturer (OEM) trained service engineers. The NovaSeq 6000 is used for Next Generation Sequencing (NGS) assays requiring high throughput and depth including Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS), Transcriptome Sequencing (RNAseq) and/or for clinical cancer panel (TSO500) performed in NCI Comprehensive Oncologic Molecular Pathology and Sequencing Service (COMPASS) clinical sequencing WGS laboratory. Accurate and trustable data generation is the most important requirement of a clinical assay, and it can be achieved through regular maintenance, proactive monitoring of the systems, and ability to fix any unexpected issues encountered at any time. Any deviation from the design specifications during the required services will compromise the integrity of data for ongoing research studies. Illumina, Inc. is the original manufacturer, distributor, and the sole provider of preventive maintenance service, emergency service, proprietary firmware maintenance/upgrades, genuine OEM replacement parts, and OEM-trained technical support for troubleshooting and diagnosing issues that arise during regular operation of the instrument. The required services are not authorized through any other entity. Additionally, the annual preventive maintenance is required to maintain laboratory accreditation with Clinical Laboratory Improvement Amendments (CLIA) and College of American Pathologists (CAP) and necessary to provide the highest standard of performance for complex clinical and scientific instruments used for clinical testing. This notice is not a request for competitive quotation. However, if any interested party, especially a small business, believes it can meet the above requirements, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain sufficient details to allow NCI to determine if the party can perform the requirement. All responses and questions must be sent via email to Contract Specialist, John Russell, at [email protected] by no later than 10:00 AM EST, on Wednesday, April 20, 2022 (04/20/22) . A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. In order to receive an award, Contractors must be registered and have valid certification through SAM.GOV. Reference: 75N91022Q00052 on all correspondence. ***Please reference attached Statement of Work for more details pertaining to the nature of the work.***